stockrowTelix Pharmaceuticals Limited
Telix Pharmaceuticals Limited’s revenue for fiscal 2025 (year ended December 2025) was $803.8 million, up 55.6% from fiscal 2024.
Follow TLX
Alert me
Telix Pharmaceuticals Limited (TLX) Return on invested capital
Telix Pharmaceuticals Limited's return on invested capital over the twelve months to 30 June 2026 was 0.00%, down 2.5 percentage points from fiscal 2025 (2.53%). That is in line with the Biotechnology industry median of 0.00% and in line with the Healthcare sector median of 0.00%.
Return on invested capital, annual
Embed this chart
Annual newest first
| Period | Return on invested capital | Change (points) |
|---|---|---|
| FY2025 | 2.53% | (10.17) |
| FY2024 | 12.7% | (10.58) |
| FY2023 | 23.3% | — |
Return on invested capital against peers
| Company | Return on invested capital |
|---|---|
| ELVN Enliven Therapeutics, Inc. compare | 0.00% |
| TARS Tarsus Pharmaceuticals, Inc. compare | 0.00% |
| VRDN Viridian Therapeutics, Inc. compare | 0.00% |
| CELC Celcuity, Inc. compare | 0.00% |
| TLX Telix Pharmaceuticals Limited | 0.00% |
| VKTX Viking Therapeutics, Inc. compare | 0.00% |
| DNLI Denali Therapeutics Inc. compare | −80.0% |
| IDYA IDEAYA Biosciences, Inc. compare | −114.2% |
| DYN Dyne Therapeutics, Inc. compare | −1,956.3% |
| Biotechnology industry median | 0.00% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Return on invested capital is
Return on Invested Capital shows how much after-tax operating profit a company earns on the money its lenders and shareholders have put in.
TTM: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) (latest quarter) + Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter) − Cash & Short Term Investments (latest quarter)); Annual: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) + Long Term Debt (Total) + Current Part of Debt − Cash & Short Term Investments)